keyword
MENU ▼
Read by QxMD icon Read
search

Triheptanoin

keyword
https://www.readbyqxmd.com/read/27884962/triheptanoin-long-term-effects-in-the-very-long-chain-acyl-coa-dehydrogenase-vlcad-deficient-mouse
#1
Sara Tucci, Ulrich Floegel, Frauke Beermann, Sidney Behringer, Ute Spiekerkoetter
A rather new approach in the treatment of long-chain fatty acid oxidation disorders is represented by triheptanoin, a triglyceride with three medium-odd-chain heptanoic acid (C7) due to its anaplerotic potential. We here investigate the effects of a one-year triheptanoin-based diet on the clinical phenotype of very long-chain-acyl-CoA-dehydrogenase-deficient (VLCAD-/-) mice. The cardiac function was assessed in VLCAD-/- mice by in vivo MRI. Metabolic adaptations were identified by the expression of genes regulating energy metabolism and anaplerotic processes using real-time-PCR and the results were correlated with the measurement of the glycolytic enzymes pyruvate dehydrogenase (PDH) and pyruvate kinase (PK)...
November 24, 2016: Journal of Lipid Research
https://www.readbyqxmd.com/read/27868154/alternative-fuels-in-epilepsy-and-amyotrophic-lateral-sclerosis
#2
Tesfaye W Tefera, Kah Ni Tan, Tanya S McDonald, Karin Borges
This review summarises the recent findings on metabolic treatments for epilepsy and Amyotrophic Lateral Sclerosis (ALS) in honour of Professor Ursula Sonnewald. The metabolic impairments in rodent models of these disorders as well as affected patients are being discussed. In both epilepsy and ALS, there are defects in glucose uptake and reduced tricarboxylic acid (TCA) cycling, at least in part due to reduced amounts of C4 TCA cycle intermediates. In addition there are impairments in glycolysis in ALS. A reduction in glucose uptake can be addressed by providing the brain with alternative fuels, such as ketones or medium-chain triglycerides...
November 21, 2016: Neurochemical Research
https://www.readbyqxmd.com/read/27590926/triheptanoin-treatment-in-patients-with-pediatric-cardiomyopathy-associated-with-long-chain-fatty-acid-oxidation-disorders
#3
J Vockley, J Charrow, J Ganesh, M Eswara, G A Diaz, E McCracken, R Conway, G M Enns, J Starr, R Wang, J E Abdenur, J Sanchez-de-Toledo, D L Marsden
Long-chain fatty acid oxidation disorders (LC-FAOD) can cause cardiac hypertrophy and cardiomyopathy, often presenting in infancy, typically leading to death or heart transplant despite ongoing treatment. Previous data on triheptanoin treatment of cardiomyopathy in LC-FAOD suggested a clinical benefit on heart function during acute failure. An additional series of LC-FAOD patients with critical emergencies associated with cardiomyopathy was treated with triheptanoin under emergency treatment or compassionate use protocols...
November 2016: Molecular Genetics and Metabolism
https://www.readbyqxmd.com/read/27564703/triheptanoin-protects-motor-neurons-and-delays-the-onset-of-motor-symptoms-in-a-mouse-model-of-amyotrophic-lateral-sclerosis
#4
Tesfaye W Tefera, Yide Wong, Mallory E Barkl-Luke, Shyuan T Ngo, Nicola K Thomas, Tanya S McDonald, Karin Borges
There is increasing evidence that energy metabolism is disturbed in Amyotrophic Lateral Sclerosis (ALS) patients and animal models. Treatment with triheptanoin, the triglyceride of heptanoate, is a promising approach to provide alternative fuel to improve oxidative phosphorylation and aid ATP generation. Heptanoate can be metabolized to propionyl-CoA, which after carboxylation can produce succinyl-CoA and thereby re-fill the tricarboxylic acid (TCA) cycle (anaplerosis). Here we tested the hypothesis that treatment with triheptanoin prevents motor neuron loss and delays the onset of disease symptoms in female mice overexpressing the mutant human SOD1G93A (hSOD1G93A) gene...
2016: PloS One
https://www.readbyqxmd.com/read/26778339/the-odd-carbon-medium-chain-fatty-triglyceride-triheptanoin-does-not-reduce-hepatic-steatosis
#5
Tine M Comhair, Sonia C Garcia Caraballo, Cornelis H C Dejong, Wouter H Lamers, S Eleonore Koehler
BACKGROUND & AIMS: Non-alcoholic fatty-liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Previously, we showed that a high-protein diet minimized diet-induced development of fatty liver and even reversed pre-existing steatosis. A high-protein diet leads to amino-acid catabolism, which in turn causes anaplerosis of the tricarboxylic-acid (TCA) cycle. Therefore, we hypothesized that anaplerosis of the TCA cycle could be responsible for the high-protein diet-induced improvement of NAFLD by channeling amino acids into the TCA cycle...
December 8, 2015: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/26547562/anaplerotic-treatment-of-long-chain-fat-oxidation-disorders-with-triheptanoin-review-of-15-years-experience
#6
Charles R Roe, Henri Brunengraber
BACKGROUND: The treatment of long-chain mitochondrial β-oxidation disorders (LC-FOD) with a low fat-high carbohydrate diet, a diet rich in medium-even-chain triglycerides (MCT), or a combination of both has been associated with high morbidity and mortality for decades. The pathological tableau appears to be caused by energy deficiency resulting from reduced availability of citric acid cycle (CAC) intermediates required for optimal oxidation of acetyl-CoA. This hypothesis was investigated by diet therapy with carnitine and anaplerotic triheptanoin (TH)...
December 2015: Molecular Genetics and Metabolism
https://www.readbyqxmd.com/read/26536893/triheptanoin-dramatically-reduces-paroxysmal-motor-disorder-in-patients-with-glut1-deficiency
#7
Fanny Mochel, Elodie Hainque, Domitille Gras, Isaac M Adanyeguh, Samantha Caillet, Bénédicte Héron, Agathe Roubertie, Elsa Kaphan, Romain Valabregue, Daisy Rinaldi, Sandrine Vuillaumier, Raphael Schiffmann, Chris Ottolenghi, Jean-Yves Hogrel, Laurent Servais, Emmanuel Roze
OBJECTIVE: On the basis of our previous work with triheptanoin, which provides key substrates to the Krebs cycle in the brain, we wished to assess its therapeutic effect in patients with glucose transporter type 1 deficiency syndrome (GLUT1-DS) who objected to or did not tolerate ketogenic diets. METHODS: We performed an open-label pilot study with three phases of 2 months each (baseline, treatment and withdrawal) in eight patients with GLUT1-DS (7-47 years old) with non-epileptic paroxysmal manifestations...
May 2016: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/26433381/modification-of-astrocyte-metabolism-as-an-approach-to-the-treatment-of-epilepsy-triheptanoin-and-acetyl-l-carnitine
#8
Mussie Ghezu Hadera, Tanya McDonald, Olav B Smeland, Tore W Meisingset, Haytham Eloqayli, Saied Jaradat, Karin Borges, Ursula Sonnewald
Epilepsy is a severe neurological disorder characterized by altered electrical activity in the brain. Important pathophysiological mechanisms include disturbed metabolism and homeostasis of major excitatory and inhibitory neurotransmitters, glutamate and GABA. Current drug treatments are largely aimed at decreasing neuronal excitability and thereby preventing the occurrence of seizures. However, many patients are refractory to treatment and side effects are frequent. Temporal lobe epilepsy (TLE) is the most common type of drug-resistant epilepsy in adults...
February 2016: Neurochemical Research
https://www.readbyqxmd.com/read/26284828/de%C3%A2-novo-fatty-acid-biosynthesis-and-elongation-in-very-long-chain-acyl-coa-dehydrogenase-deficient-mice-supplemented-with-odd-or-even-medium-chain-fatty-acids
#9
Sara Tucci, Sidney Behringer, Ute Spiekerkoetter
An even medium-chain triglyceride (MCT)-based diet is the mainstay of treatment in very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD). Previous studies with magnetic resonance spectroscopy have shown an impact of MCT on the average fatty acid chain length in abdominal fat. We therefore assume that medium-chain fatty acids (MCFAs) are elongated and accumulate in tissue as long-chain fatty acids. In this study, we explored the hepatic effects of long-term supplementation with MCT or triheptanoin, an odd-chain C7-based triglyceride, in wild-type and VLCAD-deficient (VLCAD(-/-) ) mice after 1 year of supplementation as compared with a control diet...
November 2015: FEBS Journal
https://www.readbyqxmd.com/read/26262726/hepatic-fatty-acid-profile-of-rats-fed-a-triheptanoin-based-ketogenic-diet
#10
Ingrid Sofia Vieira de Melo, Terezinha Da Rocha Ataide, Suzana Lima de Oliveira, Nassib Bezerra Bueno, Johnnatan Duarte de Freitas, Antônio Euzébio Goulart Sant'Ana
OBJECTIVE: the aim of this study was to evaluate the influence of consumption of a ketogenic diet supplemented with triheptanoin, a medium-chain anaplerotic triacylglycerol, on the liver fatty acid profile of Wistar rats. METHODS: three groups of male Wistar rats (n = 10) were submitted to an AIN-93 control diet, a triheptanoin- based ketogenic diet, or a soybean oil-based ketogenic diet for 60 days. Excised livers were subjected to lipid extraction and methylation to obtain fatty acids methyl esters, which were subjected to gas chromatography- mass spectrometry...
2015: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
https://www.readbyqxmd.com/read/26209001/triheptanoin-alleviates-ventricular-hypertrophy-and-improves-myocardial-glucose-oxidation-in-rats-with-pressure-overload
#11
T Dung Nguyen, Yasushige Shingu, Paulo A Amorim, Michael Schwarzer, Torsten Doenst
OBJECTIVE: Cardiac hypertrophy is characterized by changes in substrate utilization and activity of the Krebs cycle. We assessed the effects of triheptanoin, an odd-chain fat that might support the Krebs cycle, on cardiac metabolism and function in a model of cardiac hypertrophy. METHODS AND RESULTS: Rats were subjected to aortic banding (AoB) to induce pressure overload (PO). Starting at 1 week after AoB, rats were blindly fed a control diet or a special diet containing triheptanoin at 7% (T7 group) or 30% (T30 group) of total energy value...
November 2015: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/26116311/long-term-major-clinical-outcomes-in-patients-with-long-chain-fatty-acid-oxidation-disorders-before-and-after-transition-to-triheptanoin-treatment-a-retrospective-chart-review
#12
REVIEW
Jerry Vockley, Deborah Marsden, Elizabeth McCracken, Stephanie DeWard, Amanda Barone, Kristen Hsu, Emil Kakkis
BACKGROUND: Long chain fatty acid oxidation disorders (LC-FAODs) are caused by defects in the metabolic pathway that converts stored long-chain fatty acids into energy, leading to a deficiency in mitochondrial energy production during times of physiologic stress and fasting. Severe and potentially life threatening clinical manifestations include rhabdomyolysis, hypoglycemia, hypotonia/weakness, cardiomyopathy and sudden death. We present the largest cohort of patients to date treated with triheptanoin, a specialized medium odd chain (C7) triglyceride, as a novel energy source for the treatment of LC-FAOD...
September 2015: Molecular Genetics and Metabolism
https://www.readbyqxmd.com/read/25982559/reduced-severity-of-ischemic-stroke-and-improvement-of-mitochondrial-function-after-dietary-treatment-with-the-anaplerotic-substance-triheptanoin
#13
T M Schwarzkopf, K Koch, J Klein
Triheptanoin, an oily substance, consists of glycerol bound to three molecules of heptanoic acid, a C7 odd-chain fatty acid. A triheptanoin-rich diet has anaplerotic effects because heptanoate metabolism yields succinate which delivers substrates to the Krebs cycle. While previous studies on the effects of triheptanoin focused on metabolic disorders and epilepsy, we investigated triheptanoin's effect on ischemic stroke. Mice were fed a triheptanoin-enriched diet for 14days; controls received soybean oil. Only mice fed triheptanoin had measurable quantities of odd-numbered fatty acids in the plasma and brain...
August 6, 2015: Neuroscience
https://www.readbyqxmd.com/read/25568297/triheptanoin-improves-brain-energy-metabolism-in-patients-with-huntington-disease
#14
Isaac Mawusi Adanyeguh, Daisy Rinaldi, Pierre-Gilles Henry, Samantha Caillet, Romain Valabregue, Alexandra Durr, Fanny Mochel
OBJECTIVE: Based on our previous work in Huntington disease (HD) showing improved energy metabolism in muscle by providing substrates to the Krebs cycle, we wished to obtain a proof-of-concept of the therapeutic benefit of triheptanoin using a functional biomarker of brain energy metabolism validated in HD. METHODS: We performed an open-label study using (31)P brain magnetic resonance spectroscopy (MRS) to measure the levels of phosphocreatine (PCr) and inorganic phosphate (Pi) before (rest), during (activation), and after (recovery) a visual stimulus...
February 3, 2015: Neurology
https://www.readbyqxmd.com/read/25299635/anaplerotic-triheptanoin-diet-enhances-mitochondrial-substrate-use-to-remodel-the-metabolome-and-improve-lifespan-motor-function-and-sociability-in-mecp2-null-mice
#15
Min Jung Park, Susan Aja, Qun Li, Alicia L Degano, Judith Penati, Justin Zhuo, Charles R Roe, Gabriele V Ronnett
Rett syndrome (RTT) is an autism spectrum disorder (ASD) caused by mutations in the X-linked MECP2 gene that encodes methyl-CpG binding protein 2 (MeCP2). Symptoms range in severity and include psychomotor disabilities, seizures, ataxia, and intellectual disability. Symptom onset is between 6-18 months of age, a critical period of brain development that is highly energy-dependent. Notably, patients with RTT have evidence of mitochondrial dysfunction, as well as abnormal levels of the adipokines leptin and adiponectin, suggesting overall metabolic imbalance...
2014: PloS One
https://www.readbyqxmd.com/read/25110966/triheptanoin-for-glucose-transporter-type-i-deficiency-g1d-modulation-of-human-ictogenesis-cerebral-metabolic-rate-and-cognitive-indices-by-a-food-supplement
#16
Juan M Pascual, Peiying Liu, Deng Mao, Dorothy I Kelly, Ana Hernandez, Min Sheng, Levi B Good, Qian Ma, Isaac Marin-Valencia, Xuchen Zhang, Jason Y Park, Linda S Hynan, Peter Stavinoha, Charles R Roe, Hanzhang Lu
IMPORTANCE: Disorders of brain metabolism are multiform in their mechanisms and manifestations, many of which remain insufficiently understood and are thus similarly treated. Glucose transporter type I deficiency (G1D) is commonly associated with seizures and with electrographic spike-waves. The G1D syndrome has long been attributed to energy (ie, adenosine triphosphate synthetic) failure such as that consequent to tricarboxylic acid (TCA) cycle intermediate depletion. Indeed, glucose and other substrates generate TCAs via anaplerosis...
October 2014: JAMA Neurology
https://www.readbyqxmd.com/read/25005004/effects-of-ketogenic-diets-on-the-occurrence-of-pilocarpine-induced-status-epilepticus-of-rats
#17
Iclea Rocha Gama, Euclides Marinho Trindade-Filho, Suzana Lima Oliveira, Nassib Bezerra Bueno, Isabelle Tenório Melo, Cyro Rego Cabral-Junior, Elenita M Barros, Jaqueline A Galvão, Wanessa S Pereira, Raphaela C Ferreira, Bruna R Domingos, Terezinha da Rocha Ataide
Two sources of medium-chain triglycerides--triheptanoin with anaplerotic properties and coconut oil with antioxidant features--have emerged as promising therapeutic options for the management of pharmacoresistant epilepsy. We investigated the effects of ketogenic diets (KDs) containing coconut oil, triheptanoin, or soybean oil on pilocarpine-induced status epilepticus (SE) in rats. Twenty-four adult male Wistar rats were divided into 4 groups and fed a control diet (7% lipids) or a KD containing soybean oil, coconut oil, or triheptanoin (69...
February 2015: Metabolic Brain Disease
https://www.readbyqxmd.com/read/24288037/dietary-triheptanoin-rescues-oligodendrocyte-loss-dysmyelination-and-motor-function-in-the-nur7-mouse-model-of-canavan-disease
#18
Jeremy S Francis, Vladimir Markov, Paola Leone
The inherited pediatric leukodystrophy Canavan disease is characterized by dysmyelination and severe spongiform degeneration, and is currently refractory to treatment. A definitive understanding of core disease mechanisms is lacking, but pathology is believed to result at least in part compromised fatty acid synthesis during myelination. Recent evidence generated in an animal model suggests that the breakdown of N-acetylaspartate metabolism in CD results in a heightened coupling of fatty acid synthesis to oligodendrocyte oxidative metabolism during the early stages of myelination, thereby causing acute oxidative stress...
May 2014: Journal of Inherited Metabolic Disease
https://www.readbyqxmd.com/read/24236946/triheptanoin-partially-restores-levels-of-tricarboxylic-acid-cycle-intermediates-in-the-mouse-pilocarpine-model-of-epilepsy
#19
Mussie G Hadera, Olav B Smeland, Tanya S McDonald, Kah Ni Tan, Ursula Sonnewald, Karin Borges
Triheptanoin, the triglyceride of heptanoate, is anticonvulsant in various epilepsy models. It is thought to improve energy metabolism in the epileptic brain by re-filling the tricarboxylic acid (TCA) cycle with C4-intermediates (anaplerosis). Here, we injected mice with [1,2-(13) C]glucose 3.5-4 weeks after pilocarpine-induced status epilepticus (SE) fed either a control or triheptanoin diet. Amounts of metabolites and incorporations of (13) C were determined in extracts of cerebral cortices and hippocampal formation and enzyme activity and mRNA expression were quantified...
April 2014: Journal of Neurochemistry
https://www.readbyqxmd.com/read/24169853/alterations-of-hippocampal-glucose-metabolism-by-even-versus-uneven-medium-chain-triglycerides
#20
Tanya S McDonald, Kah Ni Tan, Mark P Hodson, Karin Borges
Medium chain triglycerides (MCTs) are used to treat neurologic disorders with metabolic impairments, including childhood epilepsy and early Alzheimer's disease. However, the metabolic effects of MCTs in the brain are still unclear. Here, we studied the effects of feeding even and uneven MCTs on brain glucose metabolism in the mouse. Adult mice were fed 35% (calories) of trioctanoin or triheptanoin (the triglycerides of octanoate or heptanoate, respectively) or a matching control diet for 3 weeks. Enzymatic assays and targeted metabolomics by liquid chromatography tandem mass spectrometry were used to quantify metabolites in extracts from the hippocampal formations (HFs)...
January 2014: Journal of Cerebral Blood Flow and Metabolism
keyword
keyword
31711
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"